US 11,925,709 B2
Tablet formulation for CGRP active compounds
Mary Ann Johnson, West Point, PA (US); Leonardo Resende Allain, Lansdale, PA (US); W. Mark Eickhoff, Lansdale, PA (US); Craig B. Ikeda, Harleysville, PA (US); Chad D. Brown, Quakertown, PA (US); Francis J. Flanagan, Jr., North Wales, PA (US); Rebecca Nofsinger, Lansdale, PA (US); Melanie Marota, Lansdale, PA (US); Lisa Lupton, South San Francisco, CA (US); Paresh B. Patel, Langhome, PA (US); Hanmi Xi, Furlong, PA (US); and Wei Xu, North Wales, PA (US)
Assigned to Merck Sharp & Dohme Corp., Rahway, NJ (US)
Filed by Merck Sharp & Dohme Corp., Rahway, NJ (US)
Filed on Dec. 3, 2020, as Appl. No. 17/110,398.
Application 17/110,398 is a continuation of application No. 16/178,641, filed on Nov. 2, 2018, abandoned.
Application 16/178,641 is a continuation of application No. 15/115,026, granted, now 10,117,836, issued on Nov. 6, 2018, previously published as PCT/US2015/013672, filed on Jan. 30, 2015.
Claims priority of provisional application 62/087,366, filed on Dec. 4, 2014.
Claims priority of provisional application 61/936,019, filed on Feb. 5, 2014.
Prior Publication US 2021/0085612 A1, Mar. 25, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/20 (2006.01); A61K 31/437 (2006.01); A61K 31/4545 (2006.01); A61K 9/14 (2006.01)
CPC A61K 9/2077 (2013.01) [A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2027 (2013.01); A61K 9/2031 (2013.01); A61K 9/2054 (2013.01); A61K 31/437 (2013.01); A61K 31/4545 (2013.01); A61K 9/146 (2013.01)] 10 Claims
 
1. A tablet comprising:
an extrudate comprising:
a water-soluble polymer matrix;
a dispersing agent; and
a compound of Formula Ia, or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein each of Rb is —H,
wherein the compound of Formula Ia is dispersed within the polymer matrix; and
a disintegration system.